Cargando…

A Novel Immunofluorescence Assay for the Rapid Serological Detection of SARS-CoV-2 Infection

As of April 2021, the COVID-19 pandemic has swept through 213 countries and infected more than 132 million individuals globally, posing an unprecedented threat to human health. There are currently no specific antiviral treatments for COVID-19 and vaccination programmes, whilst promising, remain in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Dung, Skelly, Donal, Goonawardane, Niluka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146438/
https://www.ncbi.nlm.nih.gov/pubmed/33923271
http://dx.doi.org/10.3390/v13050747
_version_ 1783697397010923520
author Nguyen, Dung
Skelly, Donal
Goonawardane, Niluka
author_facet Nguyen, Dung
Skelly, Donal
Goonawardane, Niluka
author_sort Nguyen, Dung
collection PubMed
description As of April 2021, the COVID-19 pandemic has swept through 213 countries and infected more than 132 million individuals globally, posing an unprecedented threat to human health. There are currently no specific antiviral treatments for COVID-19 and vaccination programmes, whilst promising, remain in their infancy. A key to restricting the pandemic is the ability to minimize human–human transmission and to predict the infection status of the population in the face of emerging SARS-CoV-2 variants. Success in this area is dependent on the rapid detection of COVID-19 positive individuals with current/previous SARS-CoV-2 infection status. In this regard, the ability to detect antibodies directed against the SARS-CoV-Spike protein in patient sera represents a powerful biomarker for confirmation of infection. Here, we report the design of a proof-of-concept cell–based fluorescent serology assay (termed C19-S-I-IFA) to detect SARS-CoV-2 infection. The assay is based on the capture of IgG antibodies in the serum of COVID-19-positive patients using cells exogenously expressing SARS-CoV-2-Spike and their subsequent fluorescent detection. We validate the assay in 30 blood samples collected in Oxford, UK, in 2020 during the height of the pandemic. Importantly, the assay can be modified to express emerging Spike-variants to permit assessments of the cross-reactivity of patient sera to emerging SARS-CoV-2 strains.
format Online
Article
Text
id pubmed-8146438
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81464382021-05-26 A Novel Immunofluorescence Assay for the Rapid Serological Detection of SARS-CoV-2 Infection Nguyen, Dung Skelly, Donal Goonawardane, Niluka Viruses Article As of April 2021, the COVID-19 pandemic has swept through 213 countries and infected more than 132 million individuals globally, posing an unprecedented threat to human health. There are currently no specific antiviral treatments for COVID-19 and vaccination programmes, whilst promising, remain in their infancy. A key to restricting the pandemic is the ability to minimize human–human transmission and to predict the infection status of the population in the face of emerging SARS-CoV-2 variants. Success in this area is dependent on the rapid detection of COVID-19 positive individuals with current/previous SARS-CoV-2 infection status. In this regard, the ability to detect antibodies directed against the SARS-CoV-Spike protein in patient sera represents a powerful biomarker for confirmation of infection. Here, we report the design of a proof-of-concept cell–based fluorescent serology assay (termed C19-S-I-IFA) to detect SARS-CoV-2 infection. The assay is based on the capture of IgG antibodies in the serum of COVID-19-positive patients using cells exogenously expressing SARS-CoV-2-Spike and their subsequent fluorescent detection. We validate the assay in 30 blood samples collected in Oxford, UK, in 2020 during the height of the pandemic. Importantly, the assay can be modified to express emerging Spike-variants to permit assessments of the cross-reactivity of patient sera to emerging SARS-CoV-2 strains. MDPI 2021-04-24 /pmc/articles/PMC8146438/ /pubmed/33923271 http://dx.doi.org/10.3390/v13050747 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nguyen, Dung
Skelly, Donal
Goonawardane, Niluka
A Novel Immunofluorescence Assay for the Rapid Serological Detection of SARS-CoV-2 Infection
title A Novel Immunofluorescence Assay for the Rapid Serological Detection of SARS-CoV-2 Infection
title_full A Novel Immunofluorescence Assay for the Rapid Serological Detection of SARS-CoV-2 Infection
title_fullStr A Novel Immunofluorescence Assay for the Rapid Serological Detection of SARS-CoV-2 Infection
title_full_unstemmed A Novel Immunofluorescence Assay for the Rapid Serological Detection of SARS-CoV-2 Infection
title_short A Novel Immunofluorescence Assay for the Rapid Serological Detection of SARS-CoV-2 Infection
title_sort novel immunofluorescence assay for the rapid serological detection of sars-cov-2 infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146438/
https://www.ncbi.nlm.nih.gov/pubmed/33923271
http://dx.doi.org/10.3390/v13050747
work_keys_str_mv AT nguyendung anovelimmunofluorescenceassayfortherapidserologicaldetectionofsarscov2infection
AT skellydonal anovelimmunofluorescenceassayfortherapidserologicaldetectionofsarscov2infection
AT goonawardaneniluka anovelimmunofluorescenceassayfortherapidserologicaldetectionofsarscov2infection
AT nguyendung novelimmunofluorescenceassayfortherapidserologicaldetectionofsarscov2infection
AT skellydonal novelimmunofluorescenceassayfortherapidserologicaldetectionofsarscov2infection
AT goonawardaneniluka novelimmunofluorescenceassayfortherapidserologicaldetectionofsarscov2infection